Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PHST
Do you anticiapte a selloff on the news? Seems this stock has been anticpating this since about March 5th....
Weekly chart is intersting, if volatile intra-week. you could almost swing trade it Mondat to Friday, just be sure to get back in for the next upleg Monday morning.
IDSM
m7 and I really like this chart. I am thinking of going long on it, it has a classic breakout posture here. We liken the chart to SPAZ.
Could someone sketh an outline of what this company seems to be capable of, both good and bad, from a structural point of view?
I"ll try and dig up what they are actually doing these days.
fringe
Daily and Weekly Charts below.....
Thanks aries
Man, we would never buy these things if we knoew aobut this crap ahead of time LOL.
fringe
PHST: Pharsight Reports Highest Quarterly Revenue in Company History
5/10/2007
Fiscal Year Net Income Grows 253% Year-Over-Year; Diluted EPS of $0.05 Company Issues Fiscal 2008 Guidance
MOUNTAIN VIEW, Calif., May 10, 2007 /PRNewswire-FirstCall via COMTEX News Network/ --
Pharsight Corporation (OTC Bulletin Board: PHST), a leading provider of software and strategic services designed to optimize clinical drug development, today announced financial results for its fourth quarter and fiscal year 2007, both ended March 31, 2007. Revenue for the fourth quarter was $7.3 million, the highest quarterly revenue achieved in the Company's history and reflected a 35% increase compared with revenue of $5.4 million in the fourth quarter of fiscal 2006. Revenue for the fiscal year ended March 31, 2007 grew 10% to $25.1 million and was in-line with the Company's published guidance of $25 to $26 million.
"We exited our fiscal year with strong revenue and net income growth illustrating our solid performance," said Shawn O'Connor, chairman and chief executive officer. "We were pleased to achieve revenue growth in-line with our guidance and net income that was above our guidance. We believe this success was the direct outcome of the growing mindshare and market share for our software products and consulting services, our continued execution of our revenue diversification strategy and our continued focus on operational efficiencies.
"While revenue for our software products during the fiscal fourth quarter was particularly strong and grew 52% compared with the same period of last year, fiscal year software revenue growth was 6% year-over-year," continued Mr. O'Connor. "As we have indicated in the past, due to the timing of deployments and installations of our enterprise software applications, and the related revenue recognition, quarterly and yearly software revenue growth may vary significantly. Additionally, during fiscal 2007 our software revenue was impacted by a later-than-expected launch of our newest product, the IVIVC Toolkit(TM) for WinNonlin(R), a delay in the release of WinNonlin AutoPilot(TM), and new software agreements signed later in the fiscal year than originally anticipated. As we look to fiscal 2008, we believe the upcoming release of WinNonlin AutoPilot, as well as an increased focus on software sales by our sales team, will allow us to achieve increased growth in our software revenue year-over-year.
"During the fiscal year we obtained three new Pharsight(R) Knowledgebase Server(TM) (PKS(TM)) customers," continued Mr. O'Connor. "Our newest PKS customer, added in the fiscal fourth quarter, is a premier, global specialty pharmaceutical and medical device company that discovers, develops and commercializes innovative products for the ophthalmology, neurosciences, medical dermatology, medical aesthetics and other specialty markets. This new PKS customer has more than five WinNonlin licenses and is a prime example of the success we've achieved with customers expanding their use of the Pharsight family of products. Based upon our research, customers that are using five or more seats of WinNonlin, indicating a certain level of modeling and simulation activity, should be prime candidates to expand their use of our products and recognize significant return on investment. By migrating customers to our more sophisticated products, we have the opportunity to enhance the annual recurring revenue stream for these customers, effectively expanding our software market opportunity.
"Within strategic consulting services, we continued to successfully execute our revenue diversification strategy, resulting in 16% year-over-year revenue growth in the fourth quarter and 17% year-over-year growth for the fiscal year," said Mr. O'Connor. "During the fourth quarter we entered into consulting agreements with 8 new and 15 existing customers and revenue from customers other than our top two was 46% of total strategic consulting services revenue. We exited the year with 48% of revenue derived from customers other than our top two, a positive improvement from 38% in fiscal 2006 and 30% in fiscal 2005. We believe that trends favoring the use of modeling and simulation as a meaningful tool to increase efficiency during the drug development process will allow us to continue to execute our growth strategy.
"As we have continued to explore new revenue growth opportunities, we have found that many of our customers have been looking to us for assistance on projects such as non-compartmental analysis, in-vitro/in-vivo correlation, and population pharmacokinetic/pharmacodynamic (PK/PD) modeling," continued Mr. O'Connor. "While these activities might typically be performed by junior- to mid-level pharmacokineticists in a client's organization, or outsourced by clients to a Clinical Research Organization, we believe the opportunity for us to perform these services allows us to increase the breadth and depth of our relationships with our customers. As a result, we have created a new client service offering called Reporting and Analysis Services. We believe this services offering will complement our existing software and strategic consulting services offerings and has the potential to grow into a significant contributor to our revenue growth.
"We also believe this offering leverages our strengths and core competencies including scientific expertise in pharmacokinetics and drug metabolism, software expertise in non-compartmental analysis, software experience in population PK/PD analysis and process expertise in state-of-the- art techniques for non-compartmental reporting and analysis," continued Mr. O'Connor. "Revenue for these services will be driven by our existing sales staff that currently calls on customers for software and strategic consulting services. This new unit is yet another example of our responsiveness to our customers' needs and our commitment to staying on the forefront of modeling and simulation scientific research."
Recent Highlights
Pharsight's recent highlights in its software, strategic consulting services and analysis and reporting services business units include the release of new software products, new enterprise software engagements, new consulting engagements, and expanded relationships with existing customers:
Software
-- Achieved highest quarterly revenue level for unit in Company history
representing 52% growth compared with the fourth quarter of fiscal
2006.
-- Achieved one new PKS software customer in the fourth fiscal quarter and
three during the fiscal year; PKS customers now total 19.
-- Pfizer and clinical drug researcher, Servier Laboratories Ltd., adopted
and deployed the IVIVC Toolkit for WinNonlin.
-- Released an expanded set of public source databases (meta-data) to
accelerate model-based assessment of a drug's performance against
competing therapies.
-- Launched new versions of WinNonlin and PKS Validation Suite(TM).
-- Strengthened management team by promoting Daniel Weiner, Ph.D., to
Chief Technology Officer and hiring Dana Cambra as Vice President of
R&D.
-- Added 600 new users of WinNonlin, WinNonMix(R) and Trial Simulator(TM)
in fiscal 2007.
Strategic Consulting Services
-- Achieved 16% revenue growth compared with the fourth quarter of fiscal
2006.
-- Signed 23 new consulting agreements, including those with five new
customers.
-- Presented at the 3rd Annual Pharmaceutical Sciences World Congress
(PSWC) in Amsterdam.
-- Expanded consulting services team with the addition of Fredrik Jonsson,
Ph.D. in Europe and Michelle Green, Ph.D., in the U.S.
-- Established Pharsight internship program to support emerging modeling
and simulation talent within Pharmacology, Pharmacokinetics, Chemistry,
and Biostatistics.
-- Hosted two workshops discussing the FDA's view on the role of modeling
and simulation in drug development and approval for members of the
biotechnology and pharmaceutical industries.
Reporting and Analysis Services
-- Signed three new consulting agreements during fiscal fourth quarter.
-- Hired Jean-Francois Marier, Ph.D. as Vice President, Reporting and
Analysis Services.
Additional Financial Results
Gross margin in the fourth quarter of fiscal 2007 was 68% compared with gross margin for the fourth quarter of fiscal 2006 of 64%. Year-to-date gross margin was also 69% compared with 66% for fiscal 2006.
GAAP net income for the fourth quarter of fiscal 2007 was $893,000, compared with a net loss of $261,000 in the fourth quarter of fiscal 2006 and a 78% increase compared with net income of $503,000 in the third quarter of fiscal 2007.
GAAP net income attributable to common stockholders for the fourth quarter of fiscal 2007 was $713,000, compared with a net loss attributable to common stockholders of $450,000 reported for the fourth quarter of fiscal 2006. Basic and diluted GAAP net earnings per share for the fourth quarter of fiscal 2007 were $0.04 and $0.03, respectively, compared with basic and diluted net loss per share of $0.02 in the fourth quarter of fiscal 2006.
GAAP net income for fiscal 2007 was $1.9 million, which was 253% higher than GAAP net income of $530,000 for fiscal 2006. GAAP net income for fiscal 2007 included $831,000 of stock-based compensation expense. Excluding stock-based compensation expense, non-GAAP net income for fiscal 2007 was $2.7 million, which was 410% higher than net income reported for fiscal 2006.
GAAP net income for fiscal 2007 was 7% of revenue. Excluding the impact of SFAS 123R, fiscal 2007 non-GAAP net income was 11% of revenue and exceeded the Company's guidance for non-GAAP net income to be between 5% and 10% of revenues.
GAAP net income attributable to common stockholders for fiscal 2007 was $1.1 million compared with a GAAP net loss attributable to common stockholders of $208,000 in fiscal 2006. Basic and diluted GAAP net earnings per share for fiscal 2007 were $0.06 and $0.05, respectively, compared with basic and diluted GAAP net losses per share of $0.01 for fiscal 2006. Stock-based compensation expense reduced diluted net earnings per share for fiscal 2007 by $0.04.
Cash & Liquidity
Pharsight exited the fourth fiscal quarter with cash, cash equivalents and short-term investments of $14.7 million compared with $10.8 million at the end of fiscal 2006.
Fiscal 2008 Guidance
The Company is issuing the following guidance for fiscal 2008:
-- Annual revenue growth of approximately 10% to 15% compared with fiscal
2007, or approximately $27.5 million to $29 million.
-- Gross margin of approximately 64% to 68% of revenue, depending on the
revenue mix between software, software services, strategic consulting
services and reporting and analysis services.
-- Non-GAAP net income, excluding expenses related to SFAS 123R, of
approximately 8% to 12% of revenue.
-- Diluted earnings per share of approximately $0.03 to $0.07, which
includes approximately $0.04 in expenses related to SFAS 123R.
-- Positive annual cash flow.
-- This guidance assumes that all preferred stock will be converted at the
maturity date of June 26, 2007 and that no additional dividends will be
paid following this date.
"We are very pleased that we were able to generate significant positive cash flow this fiscal year, allowing us to grow cash, cash equivalents and short-term investments by 35% year-over-year," said Will Frederick, senior vice president and chief financial officer of Pharsight. "We achieved $5.4 million in positive cash flow for the fiscal year after paying down debt of $1.5 million. This was up significantly in comparison with the $728,000 in positive cash flow we achieved in fiscal 2006 after paying down debt of $475,000. Looking ahead to fiscal 2008, we believe we can continue to grow our revenue and achieve increased earnings as our software products and consulting services gain additional mindshare within the pharmaceutical development industry."
The net income guidance for fiscal 2008 excludes any potential impact from the preferred stock dividend payable to preferred stockholders. Pharsight's preferred stockholders may elect to receive their dividend payments in the form of Series B Preferred shares instead of cash. The fair market value of such dividends if paid in the form of shares may fluctuate and may be greater or lesser than the stated value of the Series B Preferred shares. The net income guidance also excludes the pre-tax impact from stock-based compensation expense resulting from the Company's adoption of SFAS 123R in fiscal 2007. The adoption of SFAS 123R has a significant impact on the Company's result of operations, although it has no impact on its overall financial position.
While Pharsight expects that over the long-term revenues and gross margin in its software business will increase in response to customer demand, revenue and gross margin in individual quarters may fluctuate significantly in the future based upon timing of completion of large software installations and related revenue recognition.
Conference Call
Pharsight management will host a conference call and webcast tomorrow, May 11, 2007 at 10:00 a.m. Pacific Time to discuss the Company's fiscal 2007 results, outlook for fiscal 2008 and current corporate developments. The dial- in number for the conference call is 800-218-8862 for domestic participants and 303-262-2130 for international participants. To access the live webcast of the call, go to Pharsight's website at www.pharsight.com and click on the About Pharsight icon. The webcast can then be accessed under the Investor Relations section. A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will remain available for seven days. This replay can be accessed by dialing 800-405-2236 for domestic callers and 303-590-3000 for international callers, both using the passcode 11088662#.
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products. Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.
Use of Non-GAAP Financial Measures
Pharsight has provided financial information in this release that has not been prepared in accordance with GAAP. This information includes historical non-GAAP net income and guidance for fiscal 2008 non-GAAP net income. Pharsight uses these non-GAAP financial measures internally in analyzing its financial results and believes they are useful to investors, as a supplement to GAAP measures, in evaluating Pharsight's ongoing business performance and comparison to prior periods. Pharsight believes the use of these non-GAAP financial measures provides an additional tool for investors to use in comparing its financial measures with other companies in Pharsight's industry, many of which present similar non-GAAP financial measures to investors. As noted, the non-GAAP financial measures discussed above exclude stock-based compensation expense pursuant to SFAS 123R. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measure as detailed above.
Safe Harbor
This press release includes forward-looking statements, including statements regarding revenue growth, other growth strategies and opportunities, our market position and opportunities, the demand and market for our products and services, the release of new products and services, our new business unit, operating or cost efficiencies, our customer base and our relationships with our customers, and our expectations for revenue, gross margin, net income and diluted earnings per share and annual cash flow, preferred stock conversion and dividends for the fiscal year ending March 31, 2008. These forward-looking statements involve risks and uncertainties, and factors that could cause actual results to differ materially include the following: changes in the demand for Pharsight's products and services; changes in Pharsight's operating strategies, pricing models or research and development focus; the failure to develop new products and services or to keep pace with technological changes; the failure of the market for Pharsight's products and services to develop as expected; the failure to generate additional sales from existing customers or to generate sales to new customers; the failure to meet customers' expectations; uncertainties involved in pharmaceutical drug development; changes in government regulation of the pharmaceutical industry; and uncertainties regarding the redemption of our preferred stock and future dividend payments. Further information on potential factors that could affect actual results is included in Pharsight's Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission on February 12, 2007 All forward-looking statements are based on information available to Pharsight as of the date hereof, and Pharsight assumes no obligation to update such statements, whether as a result of new developments or otherwise.
NOTE: Drug Model Explorer, DMX, Pharsight, Pharsight Knowledgebase Server, PKS, PKS Validation Suite, PKS Reporter, PKS Office Client, WinNonlin, WinNonlin AutoPilot, IVIVC Toolkit for WinNonlin, and WNL Validation Suite are trademarks or registered trademarks of Pharsight Corporation.
PHARSIGHT CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)
Three Months Ended Twelve Months Ended
March 31, March 31,
2007 2006 2007 2006
Revenues:
License $1,425 $ 1,071 $ 5,402 $ 4,864
Renewal 1,568 1,289 5,652 4,928
Maintenance 277 209 1,001 977
Services 3,989 2,802 13,037 11,973
Total revenues 7,259 5,371 25,092 22,742
Cost of revenues 2,287 1,929 7,731 7,699
Gross profit 4,972 3,442 17,361 15,043
Operating expenses:
Research and 1,255 939 4,295 3,497
development
Sales and marketing 1,749 1,422 6,330 5,638
General and 1,119 1,359 5,090 5,326
administrative
Total operating 4,123 3,720 15,715 14,461
expenses
Income (loss) from
operations 849 (278) 1,646 582
Other income 105 20 372 16
Income (loss) before 954 (258) 2,018 598
income taxes
Provision for income
taxes (61) (3) (147) (68)
Net income (loss) 893 (261) 1,871 530
Preferred stock dividend (180) (189) (746) (738)
Net income (loss) $713 $(450) $1,125 $(208)
attributable to
common stockholders
Net earnings (loss) per share attributable to common
stockholders:
Basic $0.04 $(0.02) $0.06 $(0.01)
Diluted $0.03 $(0.02) $0.05 $(0.01)
Shares used to compute net earnings (loss)
per share attributable to common stockholders:
Basic 19,936 19,505 19,770 19,421
Diluted 29,578 19,505 21,562 19,421
PHARSIGHT CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
(Unaudited)
March March
31, 31,
2007 2006
ASSETS
Current assets:
Cash, cash equivalents and investments $14,665 $10,832
Accounts receivable, net 3,087 4,585
Prepaids and other current assets 523 298
Total current assets 18,275 15,715
Property and equipment, net 1,674 2,025
Other assets 46 46
Total assets $19,995 $17,786
LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK & STOCKHOLDERS'
DEFICIT
Current liabilities:
Accounts payable $769 $794
Accrued expenses 3,620 3,187
Deferred revenue 8,289 7,605
Current portion of notes payable 292 1,519
Total current liabilities 12,970 13,105
Deferred revenue, long term -- 54
Notes payable, less current portion 100 392
Other long term liabilities 179 253
Redeemable convertible preferred stock 7,096 6,641
Stockholders' deficit (350) (2,659)
Total liabilities, redeemable convertible
preferred stock and stockholders' deficit $19,995 $17,786
SOURCE Pharsight Corporation
investors, Jennifer Beugelmans, +1-646-201-5447, or Doug Sherk, +1-415-896-6820, or media, Jennifer Saunders, +1-646-201-5431, all of the EVC Group, for Pharsight http://www.pharsight.com/
Copyright (C) 2007 PR Newswire. All rights reserved
© 2007 Stockgroup Media Inc. | Disclaimer
From today's SWTS 10QSB.
As of May 7, 2007, the issuer had 17,486,013 shares of common stock outstanding, and 140,000 shares of preferred stock outstanding.
Note 8 – Subsequent Events
In April 2007, the Company entered into a one year strategic alliance with a consultant for assistance in locating and obtaining additional funding. In connection with this agreement, the Company will negotiate compensation on a project by project basis. All compensation related to the agreement will be unregistered common shares of the Company. For services to date, the consultant will receive 400,000 unregistered shares. This consultant also provided the Company with a $60,000 unsecured six month loan with interest payable at 9% upon maturity.
In April 2007, the Company entered into an agreement with a third-party consultant to provide investor relation services for a one year period in exchange for 300,000 restricted shares and a $5,000 deferred retainer fee.
In May 2007, the Company entered into an agreement with a third-party consultant to provide legal services and to act as a strategic partner in locating and obtaining financing for the Company in exchange for 750,000 restricted shares.
In May 2007, the Company entered into a one year strategic alliance with a director to provide investor relations and other business consulting services. In connection with this agreement, the Company will negotiate compensation on a project by project basis. All compensation related to the agreement will be unregistered common shares of the Company. For services to date, the consultant will receive 334,000 unregistered shares. This consultant also provided the Company with a $50,000 unsecured one year loan with interest payable at 8% upon maturity.
Subsequent to March 31, 2007 and through May 8, 2007, the Company received additional conversion requests which resulted in the conversion of $580,551 of debt and related accrued interest into 3,012,152 registered shares.
yup the 424B3 is when they can enter the market
Those shares went into "Effect" on 2/12.
http://www.sec.gov/cgi-bin/browse-edgar?company=windswept+environmental&CIK=&filenum=&St...
might be one of those throw the dd out of the window and follow momentum for a flip but no long term hold on that one imo.
They DO Know How to Play a Chart -e-
WEGI Laurus funding and waiting on the 424B3 to come out for 5,395,061 shares
SWTS to add 3,750,000 to 15,302,545 OS.
Officers and directors currently own 30% of OS. They're buried in debt, but if they pump out more positive sales info, could be interesting.
Amazon site for Sweet Success:
http://www.amazon.com/s/ref=nb_ss_hpc/104-1076015-1320747?url=search-alias%3Dhpc&field-keywords=...
Too many investors dumping and additional shares to be added. Bottom could be much lower.
Consider SWTS 0.34
Wouldn't mind being able to get a valuation on this, based on known fundamentals.
Consider AZMN 0.77
Some 8-K's, 144's and an SB-2 currently in play. Some DD is in order.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Azco Mining Intends to Proceed with Production of Summit Silver-Gold Project
Receives Outstanding Feasibility Results
Azco Mining Inc. (OTCBB:AZMN), a U.S.-based mining and exploration enterprise focused on gold, silver, copper and industrial minerals, today announced it will proceed with production of its Summit silver-gold deposit, after receiving positive pre-feasibility study results. Chapman, Wood and Griswold (“CWG”), consulting mining engineers and geologists of Albuquerque, coordinated the study of the Summit deposit in southwestern New Mexico.
Dr. Pierce Carson, Azco Mining CEO, stated, “We are pleased to announce outstanding results, especially at a time when rising precious metals prices have created an exciting climate for the company and its future prospects. CWG concludes that at today’s silver and gold prices, the Summit deposit would form the basis of an attractive and economically viable underground mining operation and that a commitment to production appears to entail minimal project risk.
“With these promising results, we are proceeding to explore avenues of financing. Once financing is in hand, we intend to immediately commit to develop the mine, construct the mill and begin production. Concurrently, we are finalizing necessary permits and preparing bid packages for mining and construction activities.”
Looking forward, Carson said cash flow generated from Summit would be important in funding the company’s future growth, including the expansion of resources at Summit, development of the Ortiz gold project and acquisition of other precious and base metal projects.
At gold and silver prices of $650 and $13 per ounce respectively, CWG estimates Summit revenues over an initial seven-year mine life would total approximately $130 million, and pre-tax net income would exceed $70 million. The company has approximately $40 million in tax loss carry-forwards to shelter federal income tax otherwise due. Direct operating costs, assuming that mine development and ore production will employ contract mining, are estimated as $76.65 per ton of ore milled. The total estimated capital cost to bring the mine into production is $13.4 million, inclusive of mine development, mill construction, bonding requirements, and project management and working capital. The economic model shows payback of capital will be achieved eighteen months after the commencement of production. CWG estimates the project could be developed and brought into production in a twelve-month time frame.
The planned mining rate at Summit is 120,000 tons of ore per year. Ore will be trucked 57 miles to the Lordsburg mill site, where it will be crushed and milled to produce a flotation concentrate. Metallurgical test work has indicated that flotation milling can achieve a recovery of 80-85 percent of the contained silver and gold. The precious metals concentrate is anticipated to grade on the order of 1,000 ounces of silver and 12 ounces of gold per ton. The study assumes that this high-grade concentrate will be marketed to one of the area copper smelters.
Silver-gold mineralization at the Summit deposit is contained in a vein-like structure in the footwall section of a 50 to 100-foot-wide, steeply-dipping, siliceous fault breccia. The mineralization of economic importance occurs across average widths of 10 to 15 feet in a zone about 1,000 feet long with a vertical dimension of 500 to 1,000 feet. The deposit is reasonably well defined by $8.5 million of exploration work carried out in the 1980s and early 1990s, including 1,550 feet of underground workings driven into the mineralized structure and core drilling totaling 78,000 feet in 88 holes. The mineralization is epithermal in nature and consists principally of finely divided argentite, electrum, and pyrite (less than 1%) in a siliceous matrix.
CWG used a minable resource estimation for the current study of 758,000 tons grading 10.28 ounces of silver per ton and 0.143 ounces of gold per ton in the main footwall zone. This estimation was adopted from a previous estimation, and represents an in-place, diluted, minable resource with a minimum six-foot horizontal width, based on results of assays from core holes and samples of underground workings. All high assay values were cut to 45 ounces of silver and 0.45 ounces of gold per ton.
CWG prepared a mine design that employs rubber-tired equipment to gain access to the minable resource through two declines, one on each end of the deposit, which will be driven from existing headings to and along the mineralized structure to a connecting point in the central part of the deposit. Further development of the deposit will continue by extending a decline to the lower limits of mineralization. Sufficient longhole drilling and trial extraction methods will be done to further plan the operation.
Carson said that establishment of the Summit mine will allow the company to further expand the resource base at the Summit deposit and to develop other properties in the Steeple Rock Mining District. The flotation mill at Lordsburg also could generate other mining and processing opportunities from surrounding mining districts, many of which historically have yielded substantial production of base and precious metals.
Azco Mining acquired the Summit deposit and Lordsburg mill site together with related operating permits in May 2006. As part of the transaction, the company also purchased a ball mill and a 400-ton-per-day flotation plant.
Should run once the SB-2 is absorbed. Chart is suggesting that will be sooner than later.
Posted by: cintrix
In reply to: None
Date:3/26/2007 9:16:05 AM
Post #of 5534
AZMN SB2 14,642,930
AZCO MINING INC 0000851726 SB-2 3/26/2007
And the bus shot is perfect. -e-
Searching for party balloons, but this is better.
BZCN revenue should be the trigger. AMRE and NAUC should follow. Just love those plays within a play within a play.
Maybe It Will Catch Some of Our Vibes -e-
I'm not serving refreshments currently, but I'll add some tunes. BYOB.
A Very nice Catch My Friend....
Hope you don't mind,but thisplace is going to get a little busier.
fringe
Looks Like It Might Break Out -e-
And PHST has rebounded. Don't have any.
UWN's done well. Caught it at $1.70. Holding for a Long.
NAUC. It's early, but chill should come off.
Time To Put Heat Back On in Here....
brrrrr! the Place is chilly. Sweep out some cobwebs.
Hey aries, wake up! Shift change.
fringe
Chat is Showing Signs
of turning. At least the important stuff is... Money Flow, Accumulation Line, and MACD.
UWN:CC on financials due today after close.
3.699 pps currently.
Looks to have bottomed. Revenue from Tioga Downs should help. Vernon Downs revenue won't kick in until next quarter.
Love To
...but off to the store to the smokes for my Ma, who's dying of cancer.
Later.
They call me fringe.
fringe
Nice PHST move in the last month.
If you have time, can you throw another chart up, fringe_remnant?
UWN (Nevada Gold) gets stronger as TPWR sinks.
Tioga Downs and Vernon Downs both opened this Summer in New York State and have been enormously successful.
Though they started out with about equal ownership in American Racing and Entertainment, UWN still owns 40% while TPWR just holds 10%. It might take another quarter, but UWN should continue moving up nicely in the next few months.
As both UWN and TPWR issued press releases today to celebrate the opening of Vernon Downs slot machines, TPWR also announced the sale of 10% interest (50% of their remaining 20%) in American Racing and Entertainment. Proceeds will pay bills they owe associated companies.
TPWR SEC 8-K filing describes sales terms.
Item 1.01: Entry into a Material Definitive Agreement
On October 23, 2006, TrackPower, Inc., (the “Company”) entered into a series of agreements to transfer 50% of its membership interest (a 10% overall interest) in American Racing and Entertainment, LLC (“American Racing”) to Southern Tier Acquisition II LLC, (“Southern Tier”) a New York Liability company and Oneida Entertainment Holdings Inc., (“Oneida) a Delaware limited liability company.
Pursuant to the agreements the Company received $2,300,000 in cash at closing. As part of the transaction the Company agreed to; 1) repay a $1,000,000 loan made by Melillo Investments in January 2006, 2) advance $1,300,000 to American Racing for past and current membership interest capital calls. In addition, Southern Tier and Oneida agreed to provide a 15% $400,000 secured loan to the Company, due on November 1, 2011. Under the terms of the loan the Company has the option on or before January 17, 2007 to obtain a further loan of $300,000 from Southern Tier and Oneida. The Company agreed to pledge as security for the loan all of its rights arising from its remaining membership interest in American Racing to Southern Tier and Oneida.
Post closing, the Company will hold a remaining 10% ownership interest in American Racing, will receive a 3.75% management fee from American Racing and will retain the $2,500,000 preferred profit distribution agreed to in 2005.
The Company agreed that until the loan, together with any interest due is paid in full, any and all distributions, payments, proceeds, management fees or an other sums paid by American Racing shall be paid directly to Southern Tier and Oneida.
Nevada Gold Announces Grand Opening of Vernon Downs Gaming Facility
HOUSTON, Oct. 26, 2006 (PRIMEZONE) -- Nevada Gold & Casinos, Inc. (AMEX:UWN), today announced the grand opening of the new 33,000 square foot gaming facility at Vernon Downs and the completion of the $4,000,000 renovation.
Visitors are enjoying all the amenities including the 777 video gaming machines. The facility's other entertainment offerings opened in August with a newly renovated grandstand, restaurants, lounges, arcades, entertainment, retail, live racing and simulcasting. Vernon Downs is located in Vernon, New York, near Syracuse.
Mr. Robert B. Sturges, Chief Executive Officer of Nevada Gold, commented, "I am extremely proud that our operating team was able to successfully open two major race track based gaming operations in less than four months. We are also very appreciative of the cooperation we received from the New York State Lottery in making these openings possible."
Mr. John Arnesen, President and Chief Operating Officer, stated, "I want to thank the 8,000 plus visitors we expect today, some of whom began lining up at seven o'clock this morning, three hours before our scheduled opening. We look forward to serving them well and making them loyal long-term guests at our facility."
Nevada Gold & Casinos, Inc., through its subsidiary Nevada Gold NY, Inc., owns a 40% interest in American Racing and Entertainment, LLC. American Racing owns 90% of Vernon Downs Acquisition, LLC, which owns the Vernon Downs Racetrack in Vernon, New York. The other members of American Racing are Southern Tier Acquisitions II, LLC, TrackPower, Inc. and Oneida Entertainment LLC, each holding 20% membership.
BZCN Hourly Chart
Repairing. Not lookin' too shabby here, getting tight again.
BZCN vs Stocklemon like YPNT vs Stocklemon?
Check the chart. YPNT rose from $2.00 to $5.00 in the three months following this press release.
YP.Net Calls Upon Stocklemon.com to Reveal the Names of its Principals, and to Disclose Their Trades Involving YP.Net Stock
Company Adds Section in Web Site to Address Stocklemon.com's Misleading Statements
Mesa, Arizona – (Business Wire)
January 13, 2004
YP.Net Inc.™ (OTC BB: YPNT), a leading provider of Internet Yellow Pages and related services, today said that in the light of Stocklemon.com’s most recent attack, it is calling upon the Internet publisher to reveal the names of its principals and to disclose their trades in YP.Net common stock. YP.Net also announced that it is in the process of creating a special section on its Web site that will be located at www.yp.com/stocklemonade.html to address in detail all of Stocklemon.com’s false allegations, as well as to document the numerous complaints about this Internet publication.
“Yesterday’s attack is another example of this publication’s use of lies to drive down the price of our stock, damaging our company and its shareholders,” stated Angelo Tullo, YP.Net’s Chief Executive Officer. “Because of the seriousness of these false accusations, we are creating a new section on our Web site to address in detail any and all allegations that are contained in this Internet publication. We challenge the anonymous publisher of Stocklemon.com to reveal his or her identity, the names of the principals and to disclose their trading activity in our stock.”
“We have said all along that the motives of Stocklemon.com and its owners and operators are highly suspect. These reports on YP.Net are filled with false and libelous statements and accusations. We believe that it is intentionally misleading for the purpose of personal gain, which we have alleged in our lawsuit,“ said DeVal Johnson, YP.Net’s Vice President.
In an article released over the weekend in the East Valley Tribune, a prominent local newspaper that interviewed the author of the negative Stocklemon.com reports, the author admitted to actively engaging in selling short the stock of companies that it investigates. In other words, Stocklemon.com and its operators engage in transactions that benefit from the fall of stock prices. Stocklemon.com conducts these transactions in company stock immediately prior or subsequent to its issuance of a negative report on the company in question – a report that often is replete with unsupported and defamatory accusations. Stocklemon.com issues these reports knowing that they are likely to drive down the stock price of the company.
“YP.Net, Inc. has sophisticated controls to insure that its financials are accurate and the company is profitable,” stated David Iannini, YP.Net’s Chief Financial Officer. “For example, in addition to the use of our outside independent auditors, we also voluntarily engage an outside independent forensic auditor that inspects our company every quarter and reports to the outside directors, management and our independent auditors.”
YP.Net has just completed the most successful year in the company's history, achieving a 144% increase in net revenues to $30.8 million and a 114% increase in net income to $7.9 million for the year (after taxes), compared to $3.7 million for the prior year. These results reflect the 125% increase in customers from 255,376 Internet Advertising Package customers from approximately 113,565 at September 30, 2002. During this time, YP.Net has paid off nearly all of its debt and has reinvested its profits in the Company, its future and stockholder value.
“We believe this entire Stocklemon.com incident was nefariously designed in an attempt to benefit short sellers by down playing the Company’s strong fundamentals and recent positive developments, such as the results of operations reported in our recent Form 10-KSB and the attainment of profitability for over 15 consecutive quarters. This is not a fluke. It is the result of a solid business model and the phenomenal efforts of our management, board of directors and team members,” Mr. Tullo concluded.
http://www.yp.com/press_release.php?releaseid=2004011301
If you look at the early NAUC/RBSY days, you'll see that once the float turned over, the action heated up considerably. Both of those started with about 5 million floats.
I expect the same for BZCN. Just a guess, though.
BZCN: Very close to that point, 2.30 I think.
BZCN very close to next leg up where the pps will be increasing by nickels and dimes instead of pennies, IMO.
When entire BZCN float turns over once, VFIN should have a whole bunch less shares to sell. With record volume of 3,324,000 shares so far today, the float is 700K shares short of turning. Action could be interesting, right around then.
AMRE/BZCN/NAUC/RBSY. Bedtime stories.
http://www.investorshub.com/boards/read_msg.asp?message_id=13708102
http://www.investorshub.com/boards/read_msg.asp?message_id=13708082
do or die huh?
<praying - DO DO DO DO!!>
BZCN Daily Trigger Chart
For what it's worth....
BZCN Chart Update
It's an Hourly Snapshot. Watch for any topping out here... ADI Green crossed down and over the ADZ recently, CMF is slowing.
The momentum is still expanding, but struggling now... see the recent PPO crossover.
This is an hourly chart. The stock is still to young to get any reliable data from a daily chart.
fringe
XNL Annotated
First posted 08.27 on the XNL Board, with a statement associated with the chart that said 'Do or Die Time for the Chart' as it was at a crossroads (the yellow circle). No fundamental analysis was made.
The chart is now updated to include for the present channel, which confirms the trend since 08.27
Fringe,
Of all people, I thought you'd be the "least" person that would get hung up in iHub politics. Especially with the way others have treated you on some of the stock specific boards.
Investors on the XNL board didn't care for your less than optimistic view but I respected your charting skills and opinion even though I was invested as well.
tsk tsk people always amaze me.
Tina
Sorry, we will watch BZCN here.
Thaks for the offer,
fringe
Followers
|
2
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
268
|
Created
|
02/13/06
|
Type
|
Premium
|
Moderator fringe_remnant | |||
Assistants aries4747 |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |